LC-MS/MS method for simultaneous Doxorubicin and Baicalein estimation: formulation and pharmacokinetic applications.

Nanomedicine (London, England) Pub Date : 2024-01-01 Epub Date: 2024-09-03 DOI:10.1080/17435889.2024.2390348

Pooja Yadav, Sanjay Singh, Divya Chauhan, Pavan Kumar Yadav, Amrendra Kumar Tiwari, Naresh Kothuri, Sonia Verma, Jvus Chakradhar, Mitali Sethi, Jiaur R Gayen, Manish Kumar Chourasia

{"title":"LC-MS/MS method for simultaneous Doxorubicin and Baicalein estimation: formulation and pharmacokinetic applications.","authors":"Pooja Yadav, Sanjay Singh, Divya Chauhan, Pavan Kumar Yadav, Amrendra Kumar Tiwari, Naresh Kothuri, Sonia Verma, Jvus Chakradhar, Mitali Sethi, Jiaur R Gayen, Manish Kumar Chourasia","doi":"10.1080/17435889.2024.2390348","DOIUrl":null,"url":null,"abstract":"Aim & objective: Combinatorial delivery of Doxorubicin (DOX) and Baicalein (BAC) has a potential to improve breast cancer treatment by mitigating the cardiotoxicity induced by DOX. The nanoformulation has been optimized and subjected to pharmacokinetic studies using LC-MS/MS.Materials & methods: Nanoformulation bearing DOX and BAC was optimized using quality by design approach and method validation was done following USFDA guidelines.Results: The particle size, PDI and zeta potential of developed nanoformulation were 162.56 ± 2.21 nm, 0.102 ± 0.03 and -16.5 ± 1.21 mV, respectively. DOX-BAC-SNEDDs had a higher AUC0-t values of 6128.84 ± 68.71 and 5896.62 ± 99.31 ng/mL/h as compared with DOX-BAC suspension.Conclusion: These findings hold promise for advancing breast cancer treatment and facilitating therapeutic drug monitoring.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"2085-2097"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11485909/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2390348","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/3 0:00:00","PubModel":"Epub","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim & objective: Combinatorial delivery of Doxorubicin (DOX) and Baicalein (BAC) has a potential to improve breast cancer treatment by mitigating the cardiotoxicity induced by DOX. The nanoformulation has been optimized and subjected to pharmacokinetic studies using LC-MS/MS.Materials & methods: Nanoformulation bearing DOX and BAC was optimized using quality by design approach and method validation was done following USFDA guidelines.Results: The particle size, PDI and zeta potential of developed nanoformulation were 162.56 ± 2.21 nm, 0.102 ± 0.03 and -16.5 ± 1.21 mV, respectively. DOX-BAC-SNEDDs had a higher AUC_0-t values of 6128.84 ± 68.71 and 5896.62 ± 99.31 ng/mL/h as compared with DOX-BAC suspension.Conclusion: These findings hold promise for advancing breast cancer treatment and facilitating therapeutic drug monitoring.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

LC-MS/MS 法同时测定多柔比星和黄芩苷：制剂和药代动力学应用

目的和目标：多柔比星（Doxorubicin，DOX）和黄芩苷（Baicalein，BAC）的联合给药有望减轻 DOX 引起的心脏毒性，从而改善乳腺癌的治疗。已对该纳米制剂进行了优化，并使用 LC-MS/MS 对其进行了药代动力学研究：材料与方法：采用质量设计法对含有 DOX 和 BAC 的纳米制剂进行了优化，并根据 USFDA 指南进行了方法验证：结果：所开发的纳米制剂的粒度、PDI 和 zeta 电位分别为 162.56 ± 2.21 nm、0.102 ± 0.03 和 -16.5 ± 1.21 mV。与 DOX-BAC 悬浮液相比，DOX-BAC-SNEDDs 的 AUC0-t 值更高，分别为 6128.84 ± 68.71 和 5896.62 ± 99.31 ng/mL/h：这些发现有望推动乳腺癌的治疗并促进治疗药物的监测。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量

期刊最新文献

Ultrasmall solid lipid nanoparticles as a potential innovative delivery system for a drug combination against glioma. Advances in Alzheimer's disease control approaches via carbon nanotubes. CD133-targeted afatinib nanomicelles for enhanced lung cancer theranostics. Correction. The emergence of inhalable RNA therapeutics and challenges faced - where to from here?